Here is Sharon Rosenzweig-Lipson’s, (the Chief Scientific officer of Life Biosciences) presentation at the December Longevity Summit on their OSK work that the company is focused on. @rapaalv
I don’t know what they are thinking regarding potential use of the conditional (doxy controlled) AAV vector in broader system applications… given its a random-integration vector it would seem to be unlikely as a platform for broad systemic use (because its a random integration vector which can cause “issues”) - but perhaps there are people here with more up-to-date knowledge about gene therapy vectors and their use who can comment here.
To me, it would seem that while this approach may work with targeted approaches (e.g ocular) where the vector is not going to likely spread more broadly, I don’t “believe” this approach would ever be practical for systemic use as it can disrupt other genes when its inserted.
It was interesting to hear that they are mostly a “virtual” company; they have less than a dozen employees and they contract most things out to CROs.
